SB 242784

Drug Profile

SB 242784

Latest Information Update: 19 Aug 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SmithKline Beecham Biologicals
  • Developer NiKem Research; SmithKline Beecham Biologicals
  • Class Indoles; Osteoporosis therapies; Piperidines
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 19 Aug 2005 Discontinued - Preclinical for Postmenopausal osteoporosis in Europe (unspecified route)
  • 20 Feb 2003 A preclinical study has been added to the Musculoskeletal pharmacodynamics section
  • 04 Dec 2002 Preclinical trials in Postmenopausal osteoporosis in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top